• Clinical science

Paroxysmal supraventricular tachycardia


Paroxysmal supraventricular tachycardia (PSVT) is a type of arrhythmia arising from a defect in atrioventricular conduction, which causes the heart to sporadically beat faster. There are different forms of PSVT, including atrioventricular nodal reentrant tachycardia (AVNRT; about two-thirds of cases), atrioventricular reentrant (or reciprocating) tachycardia (AVRT), and atrial tachycardias. In AVNRT, extra electrical conduction pathways (accessory pathways) within the AV node lead to non-extinguishable, circulating electrical impulses (reentrant circuits). AVRT, on the contrary, is caused by circular depolarizations that travel through ectopic connections between the atria and ventricles. PSVT is characterized by tachycardia attacks that may cause dizziness, dyspnea, chest pain or syncope, and are usually self-limiting. Diagnostic steps for any type of PSVT include obtaining the patient history and a 12-lead ECG, which typically shows tachycardia and narrow QRS complexes. Because most tachycardia attacks subside before an ECG is conducted, continuous recording with a Holter monitor is often needed to confirm the diagnosis. In some cases, invasive electrophysiological studies may be indicated. Patients with a congenital condition known as Wolff-Parkinson-White (WPW) syndrome commonly exhibit AVRT because of the presence of an accessory pathway known as the bundle of Kent. This pathway bypasses the AV node and transmits the sinus impulse directly to the ventricles, resulting in a premature depolarization (pre-excitation) that appears as a delta wave on ECG. Management of PSVT should be tailored to the individual patient: hemodynamically unstable patients should undergo urgent cardioversion, whereas patients who are hemodynamically stable may benefit from vagal maneuvers, e.g., carotid massage. Pharmacologic therapy is indicated if the sinus rhythm cannot be restored by vagal maneuvers. The appropriate drug depends on the conduction pathway in the heart as revealed by ECG findings. Catheter ablation may be performed as a definitive treatment.


  • Prevalence: ∼ 2.25 per 1000 people
  • Sex: > (2:1)
  • Age of onset


Epidemiological data refers to the US, unless otherwise specified.





  • The AV node contains two electrical pathways: one fast and one slow → the electrical impulse circles around the AV node within both pathways → continuous circuit that conducts impulses to the ventricles → tachycardia
  • Approx. 90% of cases are due to anterograde conduction across the slow-conducting pathway and retrograde in the fast pathway (although the reverse is possible)


Do not confuse atrioventricular reentrant (or reciprocating) tachycardia (AVRT) with atrioventricular nodal reentrant tachycardia (AVNRT)! AVRT is caused by an accessory pathway between the atrium and ventricle, while in cases of AVNRT, there are two functional pathways present within the AV node!


Clinical features




A 12-lead ECG should be performed in patients suspected of PSVT. If inconclusive, consider recording the heart's electrical activity for 24 to 48 hours with a Holter monitor or event recorder.

ECG findings in AVNRT

ECG findings in AVRT


Differential diagnoses


The differential diagnoses listed here are not exhaustive.


Hemodynamically unstable patient

Hemodynamically stable patient

  • Goal: re-establish and maintain sinus rhythm
  • Most asymptomatic patients do not require medical intervention, so observation is sufficient

Acute Management of PSVT

AV nodal blocking agents (i.e., adenosine, verapamil, beta-blockers, digoxin, amiodarone) are contraindicated in patients with signs of preexcited tachycardia on ECG (e.g., antidromic AVRT; AF in WPW patient)!

  • ECG should be recorded during acute management to identify and treat other arrhythmias if the treatment was unsuccessful
  • A defibrillator should be ready in case new dysrhythmias emerge (especially for AF)

Administration of adenosine and calcium channel blockers together may potentiate a bradycardic or hypotensive response!

Long-term management of PSVT